This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Identifying a CAP patient who may benefit from Zinforo®

Listen to Professor Antoni Torres as he discusses the challenges involved in treating community-acquired pneumonia. 

In CAP patients, initial antimicrobial therapy failure is associated with up to 5 days longer in hospital and 3x higher mortality2,8,9

George, 70-year-old nursing home resident presented with fever, cough and sputum production*

  • PORT score IV (severe)​​​​​​​
    • 70-year-old male
    • RR >30/min
    • Temperature >40°C
    • Nursing home resident
  • History of smoking
Risk factors for difficult-to-treat infection
  • Age >65 years
  • Recurrent infection (hospitalised for pneumonia 3 months ago)
  • Previous antibiotic use

Marco presented with fever, cough and pleuritic chest pain and there has been no improvement with ceftriaxone*

  • PORT score IV (severe)
    • 78-year-old male
    • Chronic renal disease
    • Pulse >125 bpm
    • RR >30/min
    • No clinical improvement within 72 hours of ceftriaxone initiation
  • Renal insufficiency
  • Recent alcoholism
Risk factors for difficult-to-treat infection​​​​​​
  • Age >65 years
  • Medical comorbidities
  • Alcoholism

Marie presented with fever, dyspnoea and cough*

  • PORT score III (moderate)
    • 56-year-old female
    • PO2<90% (upon admission)
    • Blood glucose >250 mg/dL
    • Increasing oxygen requirements to maintain oxygen saturation
  • Mild asthma
  • Diabetes
Risk factors for difficult-to-treat infection
  • Recent antibiotic exposure for URTI within previous 3 months

When there’s no time to wait, clinical trial evidence supports the use of Zinforo in your CAP patients§3,4

Explore More

Read several cSSTI patient profiles describing potential scenarios where Zinforo could be a treatment of choice. 

Access cSSTI patient profiles

To learn more about the efficacy of Zinforo in a real-world setting, explore the CAPTURE study. 

View CAPTURE study data

*The examples described here are not actual patients, but fictitious representations of scenarios for which Zinforo could be considered.
§ Refer to SmPC for further information on Zinforo1
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; ICU, intensive care unit; RR, respiratory rate; URTI, upper respiratory tract infection; PORT, Pneumonia Patient Outcomes Research Team.

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

  1. ZINFORO. Summary of Product Characteristics
  2. Ott SR, et al. Eur Respir J 2012;39:611–18
  3. File TM, et al. Clin Infect Dis 2010;51:1395–405
  4. Eckburg P, et al. Infect Dis Clin Pract 2012;51:1395–405
  5. Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18
  6. Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
  7. Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7
  8.  Ostermann H, et al. BMC Pulm Med 2014;14:36.
  9.  Menéndez R, et al. Thorax 2004;59:960–5.
PP-ZFO-GBR-0231. September 2021

Tolerability profile of Zinforo

Access date on the tolerability profile of Zinforo as established in key Phase III clinical trials.

View tolerability profile 

** This is an optional area where footnotes can live.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?